Brain Tumors: The Challenge in Brain Cancer Treatment
Glioblastoma (GBM) is the most common and aggressive form of brain tumor, yet it remains an orphan disease due to the lack of effective therapies that can meaningfully alter its bleak prognosis. Current treatments have not succeeded in significantly improving the median survival rate of 15 months, nor the five-year survival rate of only 5%.
Our Approach: Addressing Therapy Resistance in GBM
At Andremacon, we are committed to uncovering the underlying mechanisms driving therapy resistance in GBM. Our research has shown that GBM cells exploit pathways such as hypoxia to evade conventional treatments.
We are pioneering a suite of innovative molecules designed to target these mechanisms, acting as therapeutic "Trojan horses" to overcome resistance by specifically targeting cancer stem cells.
These cells are central to the tumor's aggressiveness and the remodeling of the tumor microenvironment, making them critical targets for more effective GBM therapies.
AND-C4: Our Leading Therapeutic Innovation
The lead compound in our pipeline, AND-C4, is in an advanced stage of development and represents a groundbreaking approach to GBM treatment. AND-C4 is a first-in-class therapy that selectively targets aberrant tumor pathways responsible for GBM growth, resistance, and aggressiveness. Unlike conventional therapies, AND-C4 inhibits a tumor-specific metabolic pathway, halting cancer progression without disrupting essential physiological roles related to cellular growth and maintenance.
This selectivity enables AND-C4 to focus on therapy-resistant cancer cells and cancer stem cells, blocking hypoxia-induced pathways that contribute to tumor vascularization and invasiveness. Furthermore, the versatility of AND-C4’s mechanism shows promise beyond brain tumors, potentially offering therapeutic solutions for other cancers with limited treatment options.
Enhancing the Immune Response for Comprehensive Cancer Care
In addition to its precision in targeting the tumor, AND-C4 boosts the immune system's ability to fight cancer. By enhancing the effectiveness of cell-mediated immunotherapy, AND-C4 opens up new opportunities for combination therapies, integrating immune modulation with established treatments like chemotherapy and radiotherapy.
Preclinical studies have demonstrated AND-C4’s potent anti-tumor activity, with superior penetration across the blood-brain barrier and selective accumulation within tumors. These characteristics underscore AND-C4’s potential as a transformative therapeutic option for glioblastoma patients and a promising hope for those facing limited treatment options.